ReviewMicromachines2022
Ultrasound-Responsive Nanocarriers for Breast Cancer Chemotherapy.
Review in Micromachines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Materials today. Bio · 2026Review
- Ultrasound-driven atherosclerosis nanomedicine: from mechanical, cavitation, and sonodynamic therapies to bedside translation.Journal of nanobiotechnology · 2025Review
- Better together: biomimetic nanomedicines for high performance tumor therapy.Beilstein journal of nanotechnology · 2025Review
- Nanoparticle-ultrasound synergy: an emerging theranostic paradigm for breast and gynecologic cancers.Frontiers in oncology · 2025Review
- Focused ultrasound in modern medicine: bioengineering interfaces, molecular effects, and clinical breakthroughs.Frontiers in bioengineering and biotechnology · 2025Review
- [Classification and Application of Ultrasound-Responsive Nanomaterials in Anti-Inflammatory Therapy].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Recent Update on Nanocarrier(s) as the Targeted Therapy for Breast Cancer.AAPS PharmSciTech · 2024Review
- Pathological Insights: Enhanced Vision Transformers for the Early Detection of Colorectal Cancer.Cancers · 2024Article
- Intelligent Systems based on Cyclodextrins for the Treatment of Breast Cancer.Current pharmaceutical design · 2024Review
- Vision-Transformer-Based Transfer Learning for Mammogram Classification.Diagnostics (Basel, Switzerland) · 2023Article
- Imaging-Guided Micromachines: Towards Intelligent Systems.Micromachines · 2022Article
- BUViTNet: Breast Ultrasound Detection via Vision Transformers.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer is the most common type of cancer and it is treated with surgical intervention, radiotherapy, chemotherapy, or a combination of these regimens. Despite chemotherapy's ample use, it has limitations such as bioavailability, adverse side effects, high-dose requirements, low therapeutic indices, multiple drug resistance development, and non-specific targeting. Drug delivery vehicles or carriers, of which nanocarriers are prominent, have been introduced to overcome chemotherapy limitations. Nanocarriers have been preferentially used in breast cancer chemotherapy because of their role in protecting therapeutic agents from degradation, enabling efficient drug concentration in target cells or tissues, overcoming drug resistance, and their relatively small size. However, nanocarriers are affected by physiological barriers, bioavailability of transported drugs, and other factors. To resolve these issues, the use of external stimuli has been introduced, such as ultrasound, infrared light, thermal stimulation, microwaves, and X-rays. Recently, ultrasound-responsive nanocarriers have become popular because they are cost-effective, non-invasive, specific, tissue-penetrating, and deliver high drug concentrations to their target. In this paper, we review recent developments in ultrasound-guided nanocarriers for breast cancer chemotherapy, discuss the relevant challenges, and provide insights into future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.